[3P-178] Exploring predictors of adverse events Using Urinary Metabolites in volumetric-modulated arc therapy for prostate cancer

^○Hideki Obara¹, Satoru Monzen^2,3, Yota Tatara⁴, Fumio Komai¹, Masataka Narita¹, Yoshiomi Hatayama⁵, Masahiko Aoki⁵ (1.Dept. of Rad., Div. of Med. Tech., Hirosaki Univ. Hosp., 2.Dept. of Rad., Grad. Sch. of Heal. Sci., Hirosaki Univ., 3.Res. Cent. for Biomed. Sci., Grad. Sch. of Heal. Sci., Hirosaki Univ., 4.Dept. of Stress Response Sci., Hirosaki Univ. Grad. Sch. of Med., 5.Dept. of Radiat. Oncol., Hirosaki Univ. Grad. Sch. of Med.)